3 results
Approved WMOPending
To assess the safety of treatment with escalating dosages of VELCADE in combination with ZARNESTRA in subjects with Intermediate-2 or high risk MDS according to the IPSS classification.
Approved WMOCompleted
Objective: Our main objective is to evaluate the additional effect of omega-3 fatty acids on maximal walking distance in patients with IC receiving SET. Our secondary objective is to evaluate the effect of omega-3 fatty acids on hemorheological…
Approved WMOCompleted
The primary efficacy objective is to evaluate whether LMWH is superior to VKAs in the long-term treatment of symptomatic VTE in cancer patients who completed 6 to 12 months of anticoagulant treatment. Two aspects are important: the efficacy with…